mRNA-1045

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc.

Conditions

InfluenzaRSVSARS-CoV-2

Phase 1

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

CompletedNCT05585632

ModernaTX, Inc.Influenza, RSV, SARS-CoV-2

Start: 2022-10-14End: 2024-02-28Updated: 2024-03-08

Phase 2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

CompletedNCT05606965

ModernaTX, Inc.Influenza

Start: 2022-11-02End: 2025-11-13Updated: 2025-11-24

Related Papers

Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.

2023-06-1984 citations